[PS1] Presidential Session 1
【E】

[PS1-1] Phase III of nivolumab + platinum chemotherapy + bevacizumab in untreated advanced NSQ NSCLC: Updated OS of TASUKI-52

^○Jin Hyoung Kang¹, Shunichi Sugawara², Jong-Seok Lee³, Hye Ryun Kim⁴, Naoki Inui⁵, Toyoaki Hida⁶, Ki Hyeong Lee⁷, Tatsuya Yoshida⁸, Hiroshi Tanaka⁹, Cheng-Ta Yang¹⁰, Toru Kumagai¹¹, Makoto Nishio¹², Yuichiro Ohe⁸, Tomohide Tamura¹³, Nobuyuki Yamamoto¹⁴, Chong-Jen Yu¹⁵, Hiroaki Akamatsu¹⁴, Shigeru Takahashi¹⁶, Kazuhiko Nakagawa¹⁷ (1.Department of Medical Oncology, The Catholic University of Korea, Seoul St. Mary's Hospital, 2.Department of Pulmonary Medicine, Sendai Kousei Hospital, 3.Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, 4.Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 5.Department of Pulmonary Medicine, Hamamatsu University Hospital, 6.Department of Thoracic Oncology, Aichi Cancer Center, 7.Department of Internal Medicine, Chungbuk National University Hospital, 8.Department of Thoracic Oncology, National Cancer Center Hospital, 9.Department of Internal Medicine, Niigata Cancer Center Hospital, 10.Department of Thoracic Medicine, Chang Gung Memorial Hospital, 11.Department of Thoracic Oncology, Osaka International Cancer Institute, 12.Department of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, 13.Thoracic Center, St.Luke’s International Hospital, 14.Internal Medicine III, Wakayama Medical University, 15.Department of Internal Medicine, National Taiwan University Hospital, 16.Oncology Clinical Development Planning 1, Ono Pharmaceutical Co.,LTD., 17.Department of Medical Oncology, Kindai University Faculty of Medicine)